Skip to main content
CARL
NASDAQ Life Sciences

Q3 Revenue Jumps 65% to $21.6M, Full-Year Guidance Raised to $78-80M

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.71
Mkt Cap
$401.623M
52W Low
$8.5
52W High
$17.23
52W Position info
73% above low
Off High info
15% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CARL sits 73% above its 52-week low of $8.5.

Summary

Carlsmed delivered Q3 2026 revenue of $21.6 million, up 65% from $13.1 million a year ago, and lifted full-year 2026 guidance to $78-80 million from the prior $74-78 million range — over 56% growth at the midpoint. Gross margin improved to 77.3% from 75.9%, and adjusted EBITDA loss narrowed to $7.3 million from $8.2 million. The bottom line is still red: net loss widened to $12.2 million from $8.5 million, with operating expenses up to $29.4 million including $2.8 million of executive transition and legal settlement costs. The quarter also brought new inpatient CMS reimbursement for the aprevo lumbar procedure effective October 1 and an October launch of the aprevo Lumbar Bi-lateral Posterior System, which the company estimates addresses roughly 30,000 U.S. lumbar fusion procedures annually. Cash, restricted cash, short-term investments and marketable securities totaled $80.3 million at quarter end, against a $250 million shelf registered in August that remains available for future raises.

At the time of this announcement, CARL was trading at $14.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $8.50 to $17.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CARL - Latest Insights

CARL
Nov 10, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.71
Real-time Price: $18.42 info
Change: +$3.71 (+25%) info
Market Cap: $509.716M info
CARL
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.71
Real-time Price: $18.42 info
Change: +$3.71 (+25%) info
Market Cap: $509.716M info
CARL
Sep 30, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.09
Real-time Price: $18.42 info
Change: +$4.33 (+31%) info
Market Cap: $509.716M info
CARL
Sep 15, 2026, 7:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.23
Real-time Price: $18.42 info
Change: +$3.19 (+21%) info
Market Cap: $509.716M info
CARL
Aug 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.59
Real-time Price: $18.42 info
Change: +$5.83 (+46%) info
Market Cap: $509.716M info